Name | Number of supported studies | Average coverage | |
---|---|---|---|
non-classical monocyte | 10 studies | 30% ± 9% | |
classical monocyte | 9 studies | 26% ± 12% | |
conventional dendritic cell | 9 studies | 27% ± 13% | |
natural killer cell | 7 studies | 20% ± 4% | |
endothelial cell | 7 studies | 24% ± 6% | |
monocyte | 5 studies | 22% ± 3% | |
CD8-positive, alpha-beta T cell | 5 studies | 22% ± 3% | |
hematopoietic precursor cell | 4 studies | 32% ± 15% | |
CD16-negative, CD56-bright natural killer cell, human | 4 studies | 20% ± 2% | |
epithelial cell | 4 studies | 34% ± 9% | |
ciliated cell | 4 studies | 24% ± 7% | |
macrophage | 4 studies | 25% ± 6% | |
dendritic cell | 4 studies | 38% ± 19% | |
naive thymus-derived CD8-positive, alpha-beta T cell | 3 studies | 19% ± 1% | |
B cell | 3 studies | 21% ± 6% | |
CD16-positive, CD56-dim natural killer cell, human | 3 studies | 18% ± 2% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 19% ± 3% | |
erythroblast | 3 studies | 28% ± 10% | |
hematopoietic stem cell | 3 studies | 25% ± 3% | |
plasmacytoid dendritic cell | 3 studies | 18% ± 4% | |
effector CD8-positive, alpha-beta T cell | 3 studies | 20% ± 5% | |
T cell | 3 studies | 18% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 680.49 | 180 / 180 | 100% | 42.02 | 430 / 430 |
esophagus | 100% | 789.07 | 1444 / 1445 | 100% | 36.68 | 183 / 183 |
lung | 100% | 1009.18 | 577 / 578 | 100% | 31.54 | 1150 / 1155 |
uterus | 100% | 628.28 | 170 / 170 | 99% | 45.18 | 456 / 459 |
intestine | 100% | 1016.12 | 966 / 966 | 99% | 32.23 | 522 / 527 |
stomach | 100% | 604.08 | 359 / 359 | 99% | 32.70 | 282 / 286 |
bladder | 100% | 659.14 | 21 / 21 | 98% | 31.86 | 495 / 504 |
breast | 100% | 857.65 | 459 / 459 | 98% | 28.01 | 1098 / 1118 |
thymus | 100% | 745.14 | 653 / 653 | 98% | 21.91 | 593 / 605 |
liver | 100% | 693.36 | 226 / 226 | 96% | 17.32 | 390 / 406 |
pancreas | 94% | 339.40 | 308 / 328 | 98% | 30.38 | 175 / 178 |
kidney | 100% | 706.37 | 89 / 89 | 91% | 21.47 | 820 / 901 |
prostate | 100% | 660.82 | 245 / 245 | 88% | 10.79 | 440 / 502 |
skin | 99% | 532.84 | 1798 / 1809 | 84% | 16.41 | 398 / 472 |
adrenal gland | 100% | 954.00 | 258 / 258 | 58% | 7.19 | 134 / 230 |
brain | 64% | 169.70 | 1693 / 2642 | 73% | 10.96 | 515 / 705 |
adipose | 100% | 886.84 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 46.82 | 29 / 29 |
spleen | 100% | 1933.89 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 42.34 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 21.42 | 1 / 1 |
peripheral blood | 100% | 3131.83 | 927 / 929 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 563.90 | 1324 / 1335 | 0% | 0 | 0 / 0 |
heart | 88% | 237.75 | 755 / 861 | 0% | 0 | 0 / 0 |
muscle | 61% | 141.83 | 491 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 44% | 4.54 | 35 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_1901224 | Biological process | positive regulation of non-canonical NF-kappaB signal transduction |
GO_0032687 | Biological process | negative regulation of interferon-alpha production |
GO_0045087 | Biological process | innate immune response |
GO_0009615 | Biological process | response to virus |
GO_0045089 | Biological process | positive regulation of innate immune response |
GO_1901223 | Biological process | negative regulation of non-canonical NF-kappaB signal transduction |
GO_1902524 | Biological process | positive regulation of protein K48-linked ubiquitination |
GO_0045824 | Biological process | negative regulation of innate immune response |
GO_0070936 | Biological process | protein K48-linked ubiquitination |
GO_0034142 | Biological process | toll-like receptor 4 signaling pathway |
GO_0032688 | Biological process | negative regulation of interferon-beta production |
GO_0002281 | Biological process | macrophage activation involved in immune response |
GO_0050729 | Biological process | positive regulation of inflammatory response |
GO_0007259 | Biological process | cell surface receptor signaling pathway via JAK-STAT |
GO_0005615 | Cellular component | extracellular space |
GO_0016020 | Cellular component | membrane |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0042802 | Molecular function | identical protein binding |
GO_0005515 | Molecular function | protein binding |
Gene name | NMI |
Protein name | N-myc and STAT interactor N-myc-interactor (Nmi) (N-myc and STAT interactor) |
Synonyms | |
Description | FUNCTION: Acts as a signaling pathway regulator involved in innate immune system response . In response to interleukin 2/IL2 and interferon IFN-gamma/IFNG, interacts with signal transducer and activator of transcription/STAT which activate the transcription of downstream genes involved in a multitude of signals for development and homeostasis . Enhances the recruitment of CBP/p300 coactivators to STAT1 and STAT5, resulting in increased STAT1- and STAT5-dependent transcription . In response to interferon IFN-alpha, associates in a complex with signaling pathway regulator IFI35 to regulate immune response; the complex formation prevents proteasome-mediated degradation of IFI35 . In complex with IFI35, inhibits virus-triggered type I IFN-beta production when ubiquitinated by ubiquitin-protein ligase TRIM21 . In complex with IFI35, negatively regulates nuclear factor NF-kappa-B signaling by inhibiting the nuclear translocation, activation and transcription of NF-kappa-B subunit p65/RELA, resulting in the inhibition of endothelial cell proliferation, migration and re-endothelialization of injured arteries . Negatively regulates virus-triggered type I interferon/IFN production by inducing proteosome-dependent degradation of IRF7, a transcriptional regulator of type I IFN, thereby interfering with cellular antiviral responses (By similarity). Beside its role as an intracellular signaling pathway regulator, also functions extracellularly as damage-associated molecular patterns (DAMPs) to promote inflammation, when actively released by macrophage to the extracellular space during cell injury or pathogen invasion . Macrophage-secreted NMI activates NF-kappa-B signaling in adjacent macrophages through Toll-like receptor 4/TLR4 binding and activation, thereby inducing NF-kappa-B translocation from the cytoplasm into the nucleus which promotes the release of pro-inflammatory cytokines . . |
Accessions | C9JW17 ENST00000414946.1 Q13287 ENST00000243346.10 |